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Introduction. Chronic viral hepatitis is still a major public health 
concern in the EU. In order to halt the progression of the disease 
and to prevent onward transmission, timely recognition and accu-
rate clinical management are crucial. The aim of the present study 
was to investigate the role of the general practitioner (GP) in the 
screening of persons at risk and in the clinical management of 
chronic viral hepatitis patients in six EU countries.
Methods. An online survey among GPs and secondary-care special-
ists was conducted in the UK, Germany, the Netherlands, Hungary, 
Italy and Spain. In the GP survey, we used a four-point Likert scale 
to find out how commonly risk groups are screened. In both surveys, 
we measured GPs involvement in monitoring clinical indicators 
in patients undergoing antiviral treatment, and explored whether 
patients in four clinical scenarios are referred back to primary care. 
Results. Between five and 10 experts per professional group were 
surveyed, except for Spain (GPs: n = 2; Specialists: n = 4) and, 
in the case of the GP survey, Hungary (GPs: n = 1) and Germany 
(GPs: n  =  4). Migrants are variably or not routinely screened 
for hepatitis B/C in the majority of cases. The majority of GPs 
reported that hepatitis B/C screening was routinely offered to peo-
ple who inject drugs. In Hungary, Italy and in the Netherlands, 
screening sex workers is not a regular practice. As to whether GPs 
offer screening to men who have sex with men, responses varied; 
in Germany, the Netherlands and Italy, screening was “variably” 
or “commonly” implemented, while in Hungary the practice 
seems to be sporadic. In the UK, screening for hepatitis B seems 
to be common practice among GPs, while hepatitis C testing is 
only occasionally offered to this risk group. Most GPs (> 44%) in 
all countries except Hungary reported that hepatitis B/C screen-
ing was very commonly offered to HIV patients. 
The role of GPs in monitoring hepatitis cases and the referral of 
cases back to GPs by specialists varied both within and between 
countries. GPs are unlikely to monitor clinical outcomes other 
than side effects in patients undergoing treatment. Patients who 
have had a sustained virological response are usually referred 
back to GPs, whereas patients undergoing antiviral treatment and 
those who do not respond to treatment are rarely referred back.
Conclusions. The GP’s decision to offer screening to risk groups 
often seems to be an individual choice of the healthcare pro-
fessional. Raising GPs’ awareness of the disease, for example 
through the adoption of effective strategies for the dissemination 
and implementation of the existing guidelines for general prac-
tice, is strongly needed. The role of GPs and specialists involved 
in the management of chronically infected patients should also be 
clarified, as opinions sometimes differ markedly even within each 
professional group.
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Summary
Introduction
Viral hepatitis B and C are of major public health con-
cern in the European Union, although there are dis-
tinct geographical variations in the prevalence and in-
cidence of viral hepatitis across countries. In the EU, 
the burden of disease is generally low in the north-
western countries and higher in the south-eastern re-
gion: the prevalence in the general population varies 
from 0.4% to 5.2% for anti-HCV and from 0.1% to 
5.6% for HBsAg  [1,  2]. However, as there is a lack 
of representative data in higher-risk populations, such 
as migrants from countries where hepatitis is endem-
ic  [3], the true prevalence is probably higher. In or-
der to halt the progression of the disease to advanced 
hepatic fibrosis, cirrhosis, and/or hepatocellular car-
cinoma, and to prevent onward transmission, timely 
recognition and accurate clinical management of the 
disease are of extreme importance. Both the general 
practitioner (GP) and the secondary-care specialist 
are involved in the diagnosis of chronic viral hepatitis 
and in the clinical management of infected patients. 
Several studies have explored the primary-care physi-
cian’s role and experiences in treatment and shared-
care with specialists in North America [4-6], in Aus-
tralia [7-9] and in some parts of Asia [10, 11]. To the 
best of our knowledge, however, the remit of the GP 
in the clinical management of the disease in the EU 
member states has not been extensively evaluated. 
The aim of the present study, which is part of the EU 
funded Project “HEPscreen: Screening for hepatitis B 
and C among migrants in the European Union”, was 
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to investigate, by means of a semi-quantitative online 
survey, the role of the GP in the screening of persons 
at risk and in the clinical management of chronic vi-
ral hepatitis patients in six EU countries: Germany, 
Hungary, Italy, the Netherlands, Spain and the United 
Kingdom. 
Methods
Two semi-quantitative online surveys were developed 
and administered, respectively, to general practitioners 
(GPs) and to secondary-care specialists (SPs), i.e. gastro-
enterologists, hepatologists and infectious-disease spe-
cialists, working in the six EU countries. Both surveys 
were pilot tested, translated into the national languages 
of the study countries, uploaded into the open-source on-
line software package LimeSurvey, and sent by email to 
healthcare professionals, who were board members of 
clinical associations and professional networks. Rather 
than reaching a large representative sample of practising 
clinicians, the aim was to involve 5-10 experts deemed 
able to reflect on practices within their specialty in both 
professional groups. Respondents were contacted via 
email in July  2012 and further reminded twice during 
data collection, which closed in September 2012. Data 
were exported from LimeSurvey to SPSS 19.2 (Inc. Chi-
cago, IL) for descriptive analysis. In the GP survey, we 
aimed to find out how commonly population groups at 
higher risk, namely migrants from endemic countries, 
people who inject drugs (PWID), sex workers, men 
who have sex with men (MSM), HIV positive patients 
and patients with abnormal liver function test (LFT) re-
sults, are screened for hepatitis B/C by GPs in the six 
countries. To this end, we used a four-point Likert scale 
(“very common”; “variable or not routinely”; “rarely or 
never”; “unsure”). 
In both the GP and specialist survey, the same scale 
was used to determine whether GPs were involved 
in the clinical management of patients: specifically, 
whether they were involved in monitoring alanine ami-
notransferase (ALT), viral load and side effects in pa-
tients undergoing antiviral treatment. We also explored 
whether patients were referred back to primary care in 
four clinical/patient scenarios, i.e. i) patients not quali-
fying for treatment after the initial evaluation; ii) those 
undergoing antiviral treatment; iii) those who have a 
sustained virological response (SVR) due to treatment; 
and iv) those who are non-responders to treatment. The 
replies given by the two professional groups were com-
pared.
Results
Respondent profile (Tab. I)
The respondent target of between five and 10 experts per 
professional group was achieved, except in the cases of 
Spain (GPs: n = 2; Specialists: n = 4), Hungary (GPs: 
n = 1) and Germany (GPs: n = 4) (Tab. I). 
The majority of specialists (77%) were gastroenterolo-
gists/hepatologists; 21% were infectious-disease spe-
cialists and a small proportion were community/practice 
nurses. Overall, around half of the participating GPs see 
a few (1-10) chronic hepatitis patients per year, whereas 
more than 90% of the secondary-care specialists see 
chronic hepatitis patients on a weekly basis. 
Screening by GPs for groups at higher risk 
(Tab. II)
Migrants from endemic countries. Results from the GP 
survey showed that 75% of respondents in Germany, 
56% in the Netherlands, the one in Hungary and one of 
the two in Spain stated that it was very common to offer 
hepatitis B testing to migrants from endemic regions. On 
the other hand, approximately half of the respondents in 
the UK (60%) and Italy (50%) and the other respondent 
in Spain answered that this was not routine.
Except for Hungary, where the one respondent was un-
sure, most GPs in the study countries stated that they 
either routinely or variably offered screening for hepati-
tis C to migrants from endemic regions. 
People who inject drugs. The majority of GPs from the 
UK, Germany and Italy, along with the one in Hungary 
and the two in Spain, reported that they routinely offered 
hepatitis  B/C screening to PWID. In the Netherlands, 
although screening for hepatitis C appears to be com-
monly practised by GPs for PWID, screening for hepati-
tis B varied between very commonly (44%) or variably 
(44%) offering the test.
Sex workers. In Germany and the UK most GPs (75% 
and 70%, respectively) answered that it was very com-
mon to offer a hepatitis B test to sex workers, and the 
two respondents in Spain were also of this opinion. The 
single Hungarian GP stated that it was a variable prac-
tice. In the Netherlands, respondents were split between 
judgements of “very common” and “variable”. In Italy, 
no apparent trend could be discerned.
The majority of GPs in the UK, Germany and the Neth-
erlands, and both respondents in Spain, stated that it was 
very common to recommend hepatitis C testing to sex 
workers. In Italy, most replies were split between “very 
common” and “variable”. The respondent in Hungary 
reported that it was not routinely practised.
Tab. I. Response rate by professional group and by country.
UK n (%) DE n (%) NL n (%) HU n (%) IT n (%) ES n (%) Total n (%)
GPs 10 (25) 4 (10) 9 (22.5) 1 (2.5) 14 (35) 2 (5) 40 (100)
Specialists 10 (15.6) 9 (14.1) 22 (34.4) 10 (15.6) 9 (14.1) 4 (6.3) 64 (100)
Total n (%) 20 (19.2) 13 (12.5) 31 (29.8) 11 (10.6) 23 (22.1) 6 (5.8) 104 (100)
n: number of health professionals who participated in the survey.
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Tab.  II. Frequency of screening for hepatitis B or C for population 
groups at higher risk by primary-care physicians in the six countries. 
Migrants
HBV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 20% 75% 56% 100% 14% 50%
Variable or 
not routinely 60% 25% 22% 0% 50% 50%
Rarely or 
never 10% 0% 22% 0% 29% 0%
Unsure 10% 0% 0% 0% 7% 0%
HCV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 40% 75% 67% 0% 29% 50%
Variable or 
not routinely 30% 25% 11% 0% 57% 50%
Rarely or 
never 10% 0% 22% 0% 14% 0%
Unsure 20% 0% 0% 100% 0% 0%
People who inject drugs
HBV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 90% 75% 44% 100% 64% 100%
Variable or 
not routinely 0% 25% 44% 0% 14% 0%
Rarely or 
never 0% 0% 0% 0% 14% 0%
Unsure 10% 0% 12% 0% 8% 0%
HCV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 50% 75% 67% 100% 72% 100%
Variable or 
not routinely 30% 25% 22% 0% 14% 0%
Rarely or 
never 0% 0% 11% 0% 14% 0%
Unsure 20% 0% 0% 0% 0% 0%
Sex workers
HBV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 70% 75% 44% 0% 36% 100%
Variable or 
not routinely 0% 25% 45% 100% 29% 0%
Rarely or 
never 0% 0% 11% 0% 14% 0%
Unsure 30% 0% 0% 0% 21% 0%
HCV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 60% 75% 56% 0% 36% 100%
Variable or 
not routinely 20% 25% 33% 100% 43% 0%
Rarely or 
never 0% 0% 11% 0% 14% 0%
Unsure 20% 0% 0% 0% 7% 0%
Tab. II.
Men who have sex with men
HBV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 60% 50% 44% 0% 36% 0%
Variable or 
not routinely 20% 50% 56% 100% 36% 50%
Rarely or 
never 0% 0% 0% 0% 21% 0%
Unsure 20% 0% 0% 0% 7% 50%
HCV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 20% 50% 44% 0% 36% 50%
Variable or 
not routinely 50% 50% 45% 100% 43% 50%
Rarely or 
never 0% 0% 11% 0% 21% 0%
Unsure 30% 0% 0% 0% 0% 0%
Patients with HIV
HBV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 80% 75% 67% 0% 79% 50%
Variable or 
not routinely 0% 25% 22% 100% 0% 50%
Rarely or 
never 0% 0% 0% 0% 7% 0%
Unsure 20% 0% 11% 0% 14% 0%
HCV
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 50% 75% 44% 0% 71% 100%
Variable or 
not routinely 30% 25% 22% 100% 14% 0%
Rarely or 
never 0% 0% 11% 0% 7% 0%
Unsure 20% 0% 23% 0% 8% 0%
Screening for hepatitis B for patients with abnormal 
liver funcion test results
1ST Abnormal 
Test Results
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 40% 50% 44% 100% 64% 50%
Variable or 
not routinely 50% 50% 45% 0% 22% 0%
Rarely or 
never 0% 0% 11% 0% 14% 50%
Unsure 10% 0% 0% 0% 0% 0%
2ND Abnormal 
Test Results
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 60% 100% 89% 100% 64% 50%
Variable or 
not routinely 30% 0% 11% 0% 36% 0%
Rarely or 
never 0% 0% 0% 0% 0% 50%
Unsure 10% 0% 0% 0% 0% 0%
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Men who have sex with men. As to whether GPs offer 
screening to MSM, replies indicated that it was “variably” 
and “commonly” practised in Germany, the Netherlands 
and Italy, while in Hungary it seems to be a sporadic prac-
tice. In the UK, while screening for hepatitis B seems to 
be common practice among GPs, the majority view is that 
hepatitis C testing is offered only occasionally to MSM. 
Patients with HIV. Most GPs (>  44%) in all countries 
reported that it was very common practice to offer hepa-
titis B/C screening to HIV patients, except in Hungary, 
where the respondent stated that screening was not rou-
tinely offered.
Patients with abnormal liver function test results. A first ab-
normal LFT result would very commonly prompt approxi-
mately half of the GP respondents in each country and the 
one in Hungary to screen a patient for hepatitis B, while the 
others stated that this would not routinely be the case. On 
the other hand, a second abnormal LFT result would alert 
most GPs to recommend a hepatitis B test to their patients. 
While a first abnormal LFT result would only lead half of 
the GPs to request a hepatitis C test, apart from Italy and 
Hungary, where most would ask for a hepatitis C test, a 
second or repeat abnormal LFT would prompt the majority 
of GPs in all countries to screen for hepatitis C.
The involvement of GPs in the clinical 
management of the disease (Tab. III) 
ALT. In Germany, the majority of respondents indicated 
that it was very common for GPs to monitor ALT in pa-
tients undergoing antiviral treatment. A similar, but less 
marked, trend could be seen in Italy, where over half the 
GPs selected “very common”. GPs in Spain appeared to 
be involved in monitoring ALT variably according to the 
vast majority of respondents. The trends in these three 
countries contrast with that observed in the Netherlands, 
where nearly three quarters (71%) indicated that GPs 
were rarely or never involved in monitoring ALT. In the 
UK and in Hungary, over half (55%) indicated that GPs 
were rarely or never involved, the remaining replies be-
ing distributed across the other answer options. 
Viral load. The results from both the GPs’ and special-
ists’ surveys show that, in the UK, the Netherlands, Hun-
gary and Spain, most GPs are rarely or never involved in 
monitoring viral load among patients undergoing antivi-
ral treatment. Also in Italy, despite the diverse spread of 
opinion, the largest proportion (39%) indicated that GPs 
were rarely or never involved. In Germany, a slight trend 
towards “very common” was observed.
Side effects. A diversity of opinion emerged from both 
surveys in most countries. The clearest picture emerged 
from Germany, where the majority view (62%) was that 
GPs were very commonly involved in monitoring side 
effects. The dominant view in Italy was more towards 
very common (35%) or variable (52%) monitoring of 
side effects by GPs, whereas the majority view inclined 
more towards variable to rarely or never in the UK, the 
Tab. II. 
Screening for hepatitis C for patients with abnormal 
liver funcion test results
1ST Abnormal 
Test Results
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 40% 50% 33% 100% 64% 50%
Variable or 
not routinely 40% 50% 34% 0% 29% 50%
Rarely or 
never 0% 0% 33% 0% 7% 0%
Unsure 20% 0% 0% 0% 0% 0%
2ND Abnormal 
Test Results
UK DE NL HU IT ES
(n = 10) (n = 4) (n = 9) (n = 1) (n = 14) (n = 2)
Very 
common 60% 100% 56% 100% 79% 50%
Variable or 
not routinely 20% 0% 33% 0% 22% 50%
Rarely or 
never 0% 0% 11% 0% 0% 0%
Unsure 20% 0% 0% 0% 0% 0%
Tab. III. GPs’ involvement in monitoring clinical indicators and side effects of antiviral treatment.
GPs involvement in monitoring ALT
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 20% 75% 0% 100% 64% 50%
Variable or not routinely 40% 0% 22% 0% 21% 50%
Rarely or never 20% 0% 56% 0% 14% 0%
Unsure 20% 25% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 0% 56% 0% 10% 33% 0%
Variable or not routinely 10% 11% 23% 10% 67% 100%
Rarely or never 90% 11% 77% 60% 0% 0%
Unsure 0% 22% 0% 20% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 10% 62% 0% 18% 52% 17%
Variable or not routinely 25% 8% 23% 9% 39% 83%
Rarely or never 55% 8% 71% 55% 9% 0%
Unsure 10% 23% 6% 18% 0% 0%
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Netherlands and Hungary. In Spain no majority opinion 
emerged. 
Referral back to GPs/primary care from 
specialist secondary care (Tab. IV)
Patients who do not qualify for treatment after an in-
itial evaluation. In the Netherlands and in Spain, the 
majority of respondents in both surveys agreed that pa-
tients who do not qualify for treatment after an initial 
evaluation are only variably or not routinely referred 
back to primary-care practitioners. Specialists’ opin-
ion was in contrast with that of GPs in the UK, where 
90% of specialists (vs 10% of GPs) indicated that these 
patients were rarely or never referred back to Gps. In 
Italy, although the majority of specialists (56%) se-
lected “variable”, around one third indicated “rarely or 
never”, while 57% of GPs selected “very common”. In 
Germany, the majority opinion was divided between pa-
tients being very commonly (54%) and variably (39%) 
referred back to GPs. In Hungary, no dominant opinion 
could be observed. 
Patients undergoing antiviral treatment. Overall, the 
majority of respondents in all countries (84% in the 
Netherlands, 83% in Spain, 65% in the UK, 64% in 
Hungary, 48% in Italy and 38% in Germany) stated 
that patients undergoing antiviral treatment were rarely 
or never referred back to GPs. Only in Germany and 
Italy did the majority of GPs (75% and 57%, respec-
tively) indicate that these patients were very commonly 
referred back to GPs, although around one quarter se-
lected “rarely or never”. In Germany, although 44% of 
specialists reported “rarely or never” referring back pa-
tients undergoing antiviral treatment, the same percent-
age indicated that referral was variable. In Italy, 78% of 
secondary-care specialists indicated that these patients 
were rarely or never referred back to GPs (while 57% of 
GPs stated that it was very common).
Patients with a sustained virological response due to 
treatment. In the UK, despite divergent opinions from 
GPs, most GP and specialist respondents reported that 
referral back to GPs was very common for patients who 
have SVR on account of treatment. This was also the 
dominant opinion in Germany (61%) and in the Nether-
lands (49%), where, however, 42% stated that patients 
with these characteristics were variably or not routinely 
referred back to GPs. In Hungary, opinion was divided 
between “very commonly” and “rarely or never”. In Ita-
Tab. III.
GPs involvement in monitoring viral load
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 0% 50% 0% 0% 36% 0%
Variable or not routinely 30% 25% 11% 0% 43% 50%
Rarely or never 50% 25% 67% 100% 21% 50%
Unsure 20% 0% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 0% 33% 0% 0% 22% 0%
Variable or not routinely 0% 22% 0% 10% 11% 25%
Rarely or never 100% 22% 100% 70% 67% 75%
Unsure 0% 22% 0% 20% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 0% 38% 0% 0% 30% 0%
Variable or not routinely 15% 23% 3% 9% 30% 33%
Rarely or never 75% 23% 90% 73% 39% 67%
Unsure 10% 15% 6% 18% 0% 0%
GPs involvement in monitoring side effects
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 10% 75% 0% 0% 50% 100%
Variable or not routinely 50% 0% 22% 100% 36% 0%
Rarely or never 20% 25% 56% 0% 14% 0%
Unsure 20% 0% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 10% 56% 0% 10% 11% 0%
Variable or not routinely 40% 11% 46% 20% 78% 50%
Rarely or never 50% 11% 55% 40% 11% 50%
Unsure 0% 22% 0% 30% 0% 0%
COMBINED RESPONSES UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 10% 62% 0% 9% 35% 33%
Variable or not routinely 45% 8% 39% 27% 52% 33%
Rarely or never 35% 15% 55% 36% 13% 33%
Unsure 10% 15% 7% 27% 0% 0%
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ly, although the majority judged referral to be very com-
mon, one third selected “rarely or never” and one quarter 
“variably or not routinely”. Opinion was also divided in 
Spain, where half of the respondents selected “rarely or 
never”, one third “very common”, and 17% “variably or 
not routinely”. 
Non-responders to treatment. Non-responders to treat-
ment are rarely or never referred back to GPs, accord-
ing to the majority of respondents in all countries ex-
cept Italy, where 44% stated that referral back to GPs 
was very common for these patients (the percentage 
was higher among GPs: 64%). In Germany, most re-
ported that referral back to the GP occurred variably or 
not routinely. 
Discussion
In patients with chronic viral hepatitis, shared manage-
ment based on close collaboration between the GP and 
the specialist physician, through the identification of 
their respective tasks, is necessary for the appropriate 
diagnostic and therapeutic management of the patient 
along the care pathway. Since most people with chronic 
hepatitis are asymptomatic until cirrhosis or hepatocel-
lular carcinoma are established, the initial diagnosis 
and management of chronic hepatitis relies on prima-
ry-care physicians to identify and screen high-risk in-
dividuals [12]. The GP can contribute significantly by 
promptly identifying and screening of those at risk, by 
providing counselling and information, by referring the 
patient to the specialist for disease staging and also by 
liaising/cooperating with the hospital services involved 
in the specialist management of patients. 
Non-uniform practices are likely to create or exacerbate 
health inequalities, and might be an important cause of 
the “under-treatment” phenomenon, i.e. the disparity be-
tween the number of chronic hepatitis patients and the 
number of patients actually receiving treatment  [13]. 
To our knowledge, this is the first study conducted con-
temporarily in six EU countries with the aim of investi-
gating the role of the GP in the screening practices for 
risk groups and in the clinical management of chronic 
viral hepatitis patients. Given the careful selection of 
the survey participants and national representatives of 
the experts in their respective fields, it may justifiably 
Tab. IV. Frequency of referral back to GPs for: i) patients who do not qualify for treatment after the initial evaluation; ii) patients undergoing 
antiviral treatment; iii) patients with sustained virological response due to treatment; and iv) patients who are non-responders to treatment.
Patients who do not qualify for treatment after initial evaluation
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 50% 50% 33% 100% 57% 50%
Variable or not routinely 10% 50% 56% 0% 21% 0%
Rarely or never 10% 0% 11% 0% 21% 50%
Unsure 30% 0% 0% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 10% 56% 14% 20% 11% 0%
Variable or not routinely 0% 33% 59% 30% 56% 100%
Rarely or never 90% 0% 27% 30% 33% 0%
Unsure 0% 11% 0% 20% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 30% 54% 19% 27% 39% 17%
Variable or not routinely 5% 39% 58% 27% 35% 67%
Rarely or never 50% 0% 23% 27% 26% 17%
Unsure 15% 8% 0% 18% 0% 0%
Patients undergoing antiviral treatment
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 0% 75% 11% 0% 57% 0%
Variable or not routinely 40% 0% 22% 0% 14% 0%
Rarely or never 40% 25% 56% 100% 29% 100%
Unsure 20% 0% 11% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 10% 0% 0% 10% 22% 25%
Variable or not routinely 0% 44% 5% 0% 0% 0%
Rarely or never 90% 44% 95% 60% 78% 75%
Unsure 0% 11% 0% 30% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 5% 23% 3% 9% 43% 17%
Variable or not routinely 20% 31% 10% 0% 9% 0%
Rarely or never 65% 38% 84% 64% 48% 83%
Unsure 10% 8% 3% 27% 0% 0%
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be assumed that the replies gathered provide a fair pic-
ture of the GP’s remit in the countries considered. How-
ever, caution is needed in interpreting the results where 
the respondent target of five to ten experts could not be 
reached (in Spain and Hungary). 
According to our results, the GP’s role and referral 
back to GPs vary within and between countries. What 
seems certain is that GPs are unlikely to monitor any 
clinical outcomes (such as viral load) other than some 
side effects in patients undergoing treatment, indicat-
ing that this is considered the remit of specialists in 
secondary care.
Results from a Turkish study showed that GPs were not 
able to follow up chronic viral hepatitis B and C pa-
tients because of their limited awareness of diagnostic 
facilities and treatment options [14]. Indeed, while the 
majority of GPs had adequate knowledge of HBV and 
HCV transmission and of risk factors, a low percent-
age was well informed about the treatment of chronic 
patients with elevated ALT. In particular, the Turkish 
study identified gaps in GPs knowledge of the appro-
priate use of diagnostic tests and interventions to iden-
tify and manage patients with chronic viral hepatitis. 
The authors concluded that further coordination with 
secondary-care specialists was warranted in order to 
ensure that patients were followed up in the primary-
care setting [14]. 
Strategic programmes of health education and aware-
ness-raising, for both professionals and risk groups, 
should be established. In the EU, two different strate-
gies are used to identify persons with HBV or HCV in-
fection: population screening and healthcare provider-
initiated testing (based on identified risk-factors). Pop-
ulation screening is not cost-effective, owing to the low 
prevalence of HBV and HCV infections in the general 
EU population, while the healthcare provider-initiated 
identification of HBV or HCV infection among defined 
risk groups is a valuable instrument in secondary pre-
vention. Making GPs aware of risk factors, such as de-
mographic, behavioural, occupational and medical risk 
factors, and clinical signs or symptoms of hepatitis, 
may efficiently improve case identification. Patients 
with chronic HBV or HCV infection should be referred 
for medical care and case-management, and those test-
ing negative but with risk factors for acquiring HBV or 
HCV infection should receive counselling on preven-
tion (those at risk of HBV infection should also be of-
fered vaccination) [15].
Tab. IV. 
Patients with sustained virological response due to treatment
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 10% 50% 22% 0% 57% 0%
Variable or not routinely 30% 25% 56% 0% 14% 0%
Rarely or never 20% 25% 11% 100% 29% 100%
Unsure 40% 0% 11% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 70% 67% 59% 40% 22% 50%
Variable or not routinely 10% 22% 36% 0% 44% 25%
Rarely or never 10% 0% 5% 30% 33% 25%
Unsure 10% 11% 0% 30% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 40% 61% 49% 36% 44% 33%
Variable or not routinely 20% 23% 42% 0% 26% 17%
Rarely or never 15% 8% 6% 36% 30% 50%
Unsure 25% 8% 3% 27% 0% 0%
Patients non-responders to treatment
ACCORDING TO GPs UK (n = 10) DE (n = 4) NL (n = 9) HU (n = 1) IT (n = 14) ES (n = 2)
Very common 20% 50% 11% 0% 64% 0%
Variable or not routinely 20% 25% 44% 100% 21% 0%
Rarely or never 20% 25% 22% 0% 14% 100%
Unsure 40% 0% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS UK (n = 10) DE (n = 9) NL (n = 22) HU (n = 10) IT (n = 9) ES (n = 4)
Very common 10% 11% 0% 0% 11% 25%
Variable or not routinely 0% 44% 0% 10% 33% 0%
Rarely or never 90% 33% 100% 50% 55% 75%
Unsure 0% 11% 0% 40% 0% 0%
COMBINED RESULTS UK (n = 20) DE (n = 13) NL (n = 31) HU (n = 11) IT (n = 23) ES (n = 6)
Very common 15% 23% 3% 0% 44% 17%
Variable or not routinely 10% 38% 13% 18% 26% 0%
Rarely or never 55% 31% 77% 46% 30% 83%
Unsure 20% 8% 7% 36% 0% 0%
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In the USA, approaches to the screening, diagnosis and 
management of viral hepatitis patients vary consider-
ably among primary-care physicians. Indeed, studies 
in the USA have shown deficiencies in the way some 
primary-care providers diagnose, treat or refer patients 
with HCV [16-23]. One such study investigated the as-
sociation between the characteristics of the physician 
or practice and screening and treatment for HCV infec-
tion: more experienced physicians (longer in practice) 
and those based in affluent, suburban settings were 
more likely to order ALT tests  [16]. In another study, 
a cross-sectional mail survey of 217 family physicians 
revealed insufficient levels of knowledge about screen-
ing and counselling for chronic hepatitis and hepatocel-
lular carcinoma; in addition, around half of the physi-
cians referred patients with chronic HBV or HCV to 
the specialist for further management [12]. Our results 
show that patients who have had a sustained virologi-
cal response are generally referred back to the GP, while 
patients undergoing antiviral treatment and those who 
do not respond to treatment are rarely referred back to 
primary care. 
As new treatment options, especially for hepatitis  C, 
have become available in recent years, access and ad-
herence to treatment are important determinants of the 
success of screening programmes [2]. 
Since 2012, population-based anti-HCV screening of 
all adults born between 1945 and 1965 has been rec-
ommended in the USA, where the prevalence of anti-
HCV is highest in black non-Hispanics (6.42%) and 
in Mexican Americans (3.26%) [24]. In the EU, par-
ticular attention should be paid to providing screening 
and treatment for hepatitis B and C for migrant groups 
at high risk of chronic infection. The adoption of a tar-
geted screening and treatment programme in primary 
care could be an effective strategy. Results from our 
study in the UK, suggest that standard screening prac-
tices are lacking, and allude to a shared role for GPs 
in the clinical monitoring of ALT, viral load and side 
effects. Referral back to the GP of patients undergo-
ing antiviral treatment is not common, although GPs 
and specialists differed markedly in their estimates of 
the frequency of referral back to GPs of patients who 
do not qualify for treatment. In a recent UK study, 
GPs expressed concerns about screening and treating 
patients in primary care, considering their workload 
and also the sustainability of such a strategy  [25]. 
Immigrants mentioned practical barriers, such as lan-
guage and communication difficulties, limited time 
on account of long working hours, and, in some cases, 
limited trust and confidence in general practice-based 
care [25]. 
Indeed, chronic hepatitis  B and C infections are often 
undiagnosed in primary care. According the ‘Hepatitis B 
and C surveillance in Europe – 2012’ report, in the mi-
nority of cases in which information on the testing facil-
ity was available, 27% of hepatitis B and 21% of hepati-
tis C cases were diagnosed in general practice [26]. One 
German study, involving 21,008 subjects, reported that 
the prevalence of HBsAg, anti-HCV and HCV-RNA was 
0.52%, 0.95%, and 0.43%, respectively. Infections were 
previously unknown in 85% and 65% of HbsAg- and an-
ti-HCV-positive individuals, respectively  [27]. German 
hepatitis B and C treatment guidelines recommend HB-
sAg and anti-HCV screening in several pre-defined risk 
groups. According to the participants in our survey, most 
GPs in Germany report commonly screening population 
groups at higher risk. The management of patients un-
dergoing treatment seems to be shared between GPs and 
specialists. Easy to apply guidelines with defined risk 
scenarios may help to diagnose previously unknown in-
fections [27]. Previous results from the HEPscreen Pro-
ject showed that the availability of training programmes 
to improve skills and knowledge of viral hepatitis dif-
fered across the six EU countries. Among the experts 
interviewed (268 health professionals), 80% and 73% 
were aware of hepatitis B and hepatitis C guidelines, 
respectively, in their country  [28]. The findings of the 
present study could provide impetus to the formulation 
of precise and clear guidelines targeting primary-care 
physicians and secondary-care specialists. These should 
explicitly specify, in a shared-care model, the different 
responsibilities in the management of chronic hepatitis 
patients, so as to deliver more effective healthcare.
Conclusions
Although the GP’s role in the screening and clinical 
management of chronic viral hepatitis is crucial to timely 
diagnosis and linkage to specialist care, the diversity of 
responses often observed suggests inadequate awareness 
of explicit recommendations, which results in a lack of 
uniform practices among experts. The GP’s decision to 
offer screening to risk groups often seems to be an indi-
vidually motivated choice of the healthcare professional. 
The inconsistencies observed in screening practices may 
mean that many chronic infections remain undetected. 
This underscores the need to raise GPs’ awareness of 
this silent epidemic, for example through the adoption of 
effective strategies for the dissemination and implemen-
tation of the existing guidelines for general practice. The 
role of GPs and specialists involved in the management 
of chronically infected patients should also be clarified, 
as opinions sometimes differed markedly even within 
each professional group. 
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